10.1186/s12902-022-01036-0 67
Melanotan-I and -II" Pharmaceutical Biotechnology, 11:575-595 "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study" Life Sciences, 58(20):1777-1784 "Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge" European Journal of Pharmacology, 660(1):88-93 "Targeting melanocortin receptors as a novel strategy to control inflammation" Pharmacological Reviews, 56(1):1-29 "Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations" Journal of the American Chemical Society, 111(9):3413-3416 Produkt jest surowcem chemicznym przeznaczonym wycznie do zastosowa badawczych, naukowych i analitycznych in vitro

The first line segment dominated the GLP-1 targeted peptide weight loss drugs market in 2024 and is expected to continue its growth trajectory in the upcoming period, as these drugs are increasingly being prescribed early in the treatment of obesity and related metabolic conditions
The results suggested that 30 min pre- or post-irradiation treatment of mitoperoxidase 2 significantly protected the mouse embryonic cells from radiation (10 Gy)-induced apoptosis by reducing the extent of mitochondrial ROS generation and lipid peroxidation
V.SaravananG